G.E. Morrison et al, AV650 poster, “AV650 (tolperisone HCl) – A Centrally Acting, Non-Sedative Muscle relaxant for the Treatment of Spasticity. First in Human Study Results.” Mechanisms and Treatment of Neuropathic Pain, Nov. 2007
Avigen Product Information Bulletin No. 1 – “Tolperisone HCI (AV650) and Query of Cardiac QT Prolongation,” April 2006
Avigen Product Information Bulletin No. 2 – “Tolperisone and Anaphylaxis,” April, 2006
P. Stamenova et al, “A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke,” European J. of Neurology, 2005; 12:453-461
Khodinka Laszlo et al (translation from Russian), “Treatment of acute lumbar pain with Mydocalm. The results of the multi-centre international randomized double-blind placebo-controlled clinical trial.” Russian Medical Journal, 2003; vol. 11
R. Kohne-Volland (translation from Russian), “The clinical trial of Mydocalm (tolperisone of hydrochloride),” pamphlet devoted to the clinical trial of the effectiveness and safety of Mydocalm treatment for rheumatological patients, carried out in Germany under the aegis of Richter Gedeon Ltd. (Hungary) and Strathmann AG (Germany), 1999
J. Dulin et al, “Evaluation of sedative effects of single and repeated doses of 50 mg and 150 mg tolperisone hydrochloride. Results of a prospective, randomized, double-blind, placebo-controlled trial,” J. Pharmacopsychiatry, 1998; 31:137-142
H.G. Pratzel et al, “Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial,” Pain, 1996; 67:417-425
Miklos Feher et al, “Effect of Mydeton in the rehabilitation of hemipretic patients,” Balneology and Rehabilitation, 1985; 6:201-205
Package Insert – Vivio® [Tolperisone (HCl)], Orion/Sanochemia [marketed in Germany, translation from Germany], May 2007
AV 411
M.R. Hutchinson et al, abstract, “Improving the safety and efficacy of opioids by attenuating glial activation: clinical implications & the search for the novel glial activation site,” 37th Annual Meeting of the Society for Neuroscience, Nov. 2007
Hutchinson, et al. Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence and reward. NIDA-requested review in The Scientific World Journal 2007; 7(S2), 98-111
Ledeboer, A., et al, Johnson, K.W., et al., and Watkins, L.R. Intrathecal Interleukin-10 Gene Therapy Attenuates Paclitaxel-Induced Mechanical Allodynia and Proinflammatory Cytokine Expression in Dorsal Root Ganglia in Rats. Brain, Behavior, Immunity (Glia/Pain special issue), Brain Behav Immun. 2007; 21:686-698
Ledeboer, A. et al, and Johnson, K.W. The Glial Modulatory Drug AV411 Attenuates Mechanical Allodynia in Rat Models of Neuropathic Pain. Neuron Glia Biology (Pain special issue) 2007; 2:279-291
Ledeboer, A., Hutchinson, M., Watkins, L., and Johnson, K. Ibudilast (AV411): a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opinion on Investigational Drugs, 2007; 16:935-950
Linda R. Watkins et al, “Glia as the ‘bad guys’: Implications for improving clinical pain control and the clinical utility of opioids,” Norman Cousins Lecture, Brain, Behavior, and Immunity, 2007; 21:131-146
Claypool et al, AV411 poster, “Phosphodiesterase inhibition by AV411 (ibudilast) may contribute to its efficacy in rat models of acute nociception and paclitaxel-induced neuropathic pain.” Soc. for Neuroscience, Nov. 2007
Gross et al, AV1013 poster, “AV1013, A Novel orally active glial inhibitor, attenuates mechanical allodynia in rat pain models.” Mechanisms and Treatment of Neuropathic Pain, Nov. 2007
Ledeboer et al, abstract, “Novel approaches to control paclitaxel-induced neuropathic pain: Efficacy of interleukin-10 gene therapy and the blood-brain barrier permeable glial modulator, AV411,” Brain, Behavior, and Immunity, May 2006; v. 20, issue 3, Supplement 1: p. 43
Ledeboer et al, abstract, “AV411, a blood-brain barrier permeable glial inhibitor, attenuates chronic constriction injury (CCI)- and paclitaxel-induced neuropathic pain,” The Journal of Pain, April 2006; v. 7, issue 4, Supplement S: p. 7
Ledeboer, E.M. Sloane, E.D. Milligan, S.J. Langer, S.F. Maier, K.W. Johnson, L.A. Leinwand, R.A. Chavez, L.R. Watkins, “Paclitaxel-induced mechanical allodynia in rats is inhibited by spinal delivery of plasmid DNA encoding interleukin-10.” In: H. Flor, E. Kalso, J.O. Dostrovsky (Eds): Proceedings of the 11th World Congress on Pain, International Association for the Study of Pain, 2006, pp.187-194
Lewis et al, AV411 poster, “AV411, a blood brain barrier permeable glial activation inhibitor, reduces morphine withdrawal behaviors in rats,” Soc. for Neuroscience, Oct. 2006
Liu et al, AV411 poster, “AV411, A Novel attenuator of neuropathic pain (and morphine withdrawal),” Mechanisms and Treatment of Neuropathic Pain, Nov. 2005
E.D. Milligan, S.J. Langer, E.M. Sloane et al, “Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10,” Eur J. Neurosci., 2005; 21:2136-2148
E.D. Milligan, E.M. Sloane, S.J. Langer et al, “Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10,” Mol Pain. 2005; 1:9
Tetsuya Mizuno et al, “Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia,” Neuro Pharmacology, 2004; 46: 404-411
Linda R. Watkins and Steven F. Maier – “When good pain turns bad,” Current Directions in Psychological Science, 2003; vol. 12, no. 6:232-236
Vesa K. Kontinen and Theo F. Meert, “Predictive Validity of Neuropathic Pain Models in Pharmacological Studies with a Behavioral Outcome in the Rat: A Systematic Review,” Proceedings of the 10th World Congress on Pain, 2003; 24:489-498
K.M. Foley, “Opioids and chronic neuropathic pain,” N Engl J Med. 2003; 348:1279-1281
“Decade of pain control and research: Now is the time to do something about America's pain crisis” [press release]. American Pain Society; September 24, 2003
M. Pohl, A. Meunier, M. Hamon, J. Braz, “Gene therapy of chronic pain,” Curr Gene Ther., 2003; 3:223-238
W.F. Stewart, J.A. Ricci, E. Chee, D. Morganstein, R. Lipton, “Lost productive time and cost due to common pain conditions in the U.S. workforce,” JAMA. 2003; 290:2443-2454
T. Hampton, “Researchers probe pathways of pain: new insights emerging from molecular studies,” JAMA, 2003; 290:2391-2392
M.L. Meldrum, “A capsule history of pain management,” JAMA, 2003; 290:2470-2475
J. C. Ballantyne, J. Mao, “Opioid therapy for chronic pain,” N Engl J Med., 2003; 349:1943-1953
L. R. Watkins, S.F. Maier, “Glia: a novel drug discovery target for clinical pain,” Nat Rev Drug Discov. 2003; 2:973-985
M.B. Max, “How to move pain and symptom research from the margin to the mainstream,” J Pain. 2003; 4:355-360
Linda R. Watkins and Steven F. Maier, “Beyond Neurons: Evidence That Immune and Glial Cells Contribute to Pathological Pain States,” Physiological Reviews, 2002; 82:981-1011
Linda S. Sorkin, “Neuroinflammation, cytokines and neuropathic pain” (book chapter, Mechanisms and Mediators of Neuropathic Pain), Annika B. Malmberg and Sandra R. Chaplan, editors, 2002
B.A. Vogt, “Knocking out the DREAM to study pain,” N Engl J Med., 2002; 347:362-364
Package Insert – Ketas®, 2003
Package Insert – Cymbalta®, 2005
Package Insert - Neurontin®, 2005
AV 513
S. Prasad, et al, and K. Johnson, “Efficacy and Safety of a New-Class Drug Candidate, AV513, in Hemophilia A Dogs,” Blood, 15 Jan. 2008; Vol. 111, No. 2:672-679
S. Knappe et al, abstract, “AV513 enhances tissue factor activity and stimulates thrombin generation in Hemophilia A plasma,” Oral presentation at the International Society of Thrombosis and Haemostasis, Geneva, Switzerland, 2007
S. Prasad et al, abstract, “Preclinical pharmacology of AV513 including oral efficacy in severe Hemophilia A dogs,” Oral presentation at the International Society of Thrombosis and Haemostasis, Geneva, Switzerland, 2007
N.J. Mutch et al, abstract, “Non-Anticoagulant sulfated polysaccharides enhance thrombin generation by accelerating factor V activation,” Oral presentation at the International Society of Thrombosis and Haemostasis, Geneva, Switzerland, 2007
S. Knappe et al, abstract, “AV513 enhances tissue factor activity by inhibiting TFPI in hemophilia A Plasma: potential TFPI target sites and potentiation of Factor VIII activity,” Oral presentation at the American Society of Hematology, Atlanta, USA, 2007
E.G.D. Tuddenham editorial, “Ways to bypass a blocked tenase complex,” Thrombosis and Haemostasis, 2006; vol. 95, no. 1:1-2
Liu et al, “Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP),” Thrombosis and Haemostasis, 2006; vol. 95, no. 1:68-76
D. Lillicrap et al, abstract, “A therapeutic benefit from Non-Anticoagulant Sulfated Polysaccharide (NASP) treatment in hemophilic dogs,” Presented at: World Federation of Hemophilia 2006 Congress
